NCT00369226View on ClinicalTrials.gov

Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

July 31, 2010

Study Completion Date

September 30, 2011

Conditions
Hematologic Malignancies
Interventions
DRUG

Bortezomib (Velcade)

Infusion for a total of 3 doses

DRUG

Tacrolimus

Taken until Doctor determines it is not necessary any more

DRUG

Methotrexate

Infusion for a total of 4 doses

PROCEDURE

blood stem cell transplantation

Allogeneic Non-myeloablative peripheral blood stem cell transplantation

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER